Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Giuliani

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Annals of Maxillofacial Surgery|March 17, 2017
A rare case of parotid gland lipoma arising from the deep lobe of the parotid glandFrancesco Paparo, Mauro Massarelli, Giorgio Giuliani
The Cochrane Database of Systematic Reviews|October 7, 2011
Natalizumab for relapsing remitting multiple sclerosisEugenio Pucci, Giorgio Giuliani, Alessandra Solari, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|July 29, 2024
Brain Death Donors on Extracorporeal Membrane Oxygenation SupportManuela Bonizzoli, Chiara Lazzeri, Simona Di Valvasone, et al.
Journal of Neurology|October 1, 2008
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal respondersLuca Durelli, Pierangelo Barbero, Mauro Bergui, et al.
Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.
Plos One|July 7, 2012
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeClaire Meyniel, Timothy Spelman, Vilija G Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Annals of Maxillofacial Surgery|March 17, 2017
A rare case of parotid gland lipoma arising from the deep lobe of the parotid glandFrancesco Paparo, Mauro Massarelli, Giorgio Giuliani
The Cochrane Database of Systematic Reviews|October 7, 2011
Natalizumab for relapsing remitting multiple sclerosisEugenio Pucci, Giorgio Giuliani, Alessandra Solari, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|July 29, 2024
Brain Death Donors on Extracorporeal Membrane Oxygenation SupportManuela Bonizzoli, Chiara Lazzeri, Simona Di Valvasone, et al.
Journal of Neurology|October 1, 2008
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal respondersLuca Durelli, Pierangelo Barbero, Mauro Bergui, et al.
Neurology|March 11, 2014
Fingolimod after natalizumab and the risk of short-term relapseVilija G Jokubaitis, Vivien Li, Tomas Kalincik, et al.
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.
Neurology. Clinical Practice|April 23, 2016
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MSTim Spelman, Tomas Kalincik, Vilija Jokubaitis, et al.
Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.
Plos One|July 7, 2012
Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeClaire Meyniel, Timothy Spelman, Vilija G Jokubaitis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 30, 2011
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase RegistryStella Hughes, Timothy Spelman, Maria Trojano, et al.
Pageof 2